What is the purpose of this study?
The purpose of this clinical trial is to evaluate the efficacy, safety and tolerability of BMS241027, a drug that may have the potential to treat Alzheimer's disease (AD). In AD, there are abnormally-high levels of a protein, called tau, in the fluid surrounding the brain. We hope that BMS241027 can decrease the levels of tau.
Who is eligible?
We are looking for participants who:
-- have been diagnosed with mild Alzheimer's disease
-- are between the age of 50 and 90
-- have a reliable caregiver or family member who is able to accompany them to study visits
-- are in stable medical condition
-- are willing to undergo MRI and lumbar punctures
People taking approved Alzheimer's medications (donepezil/Aricept, galantamine/Razadyne, rivastigmine/Exelon, memantine/Namenda) are eligible to take part in this study and can continue taking these medications during the study.
Please see the attached study description for more information.
|BMS web blurb.doc ||37 KB|